Contact Us: 1-518-583-0095 
We’re Hiring… Join Our Team!
This is the first clinical trial to investigate CPD in multiple myeloma. Results suggest that the regimen is a well-tolerated and highly active combination for patients with relapsed/refractory multiple myeloma.
Continue readingCriterium, Inc., a full-service CRO is pleased to announce the promotions of our two newest consortia directors, Drs D. Ross Camidge and Peter Kabos, both from the University of Colorado. Dr Camidge, Director for the ATOMIC Consortia for Thoracic and Lung Cancers, was recently promoted from his current position of Associate Professor, Division of Medical Oncology to “Professor with Tenure”. Dr Kabos, Director for the ABRCC Consortia for Breast Cancer, was recently promoted from his current position of Assistant Professor, Division of Medical Oncology to “Associate Professor”.
Continue readingCriterium, Inc., a full service global CRO is pleased to announce the formation of its two new oncology consortia: ATOMIC (The Academic Thoracic Oncology Medical Investigator’s Consortium) focusing on Thoracic and Lung Cancers, and ABRCC (The Academic Breast Cancer Consortium), dedicated to Breast Cancer research.
Continue readingThe Academic Myeloma Consortium (AMyC) was present at the December 2011 ASH meeting. The Consortium is part of the CORE Science Solutions (CSS) group of Consortia focused on collaborating with pharmaceutical and biotech companies on the development of drugs to treat myeloma. CSS is part of the Criterium Inc. group of companies.
Continue readingAptium Oncology, a consulting and management company for cancer centers, is putting together a network of investigators specifically focused on myeloma and related cancers. The Aptium Oncology Myeloma Consortium (AMyC) is modeled after Aptium’s GI Cancer Consortium, a group launched in 2008 to focus on gastrointestinal cancers.
Continue readingAptium Oncology, Inc. announced the launch of Aptium Oncology Myeloma Consortium (AMyC), a broad-based collaboration that brings together renowned investigators to work with pharmaceutical sponsors to advance clinical and translational research in myeloma and related cancers.
Continue readingAt the 19th IASLC World Conference on Lung Cancer in Toronto, Canada, the top 5 abstracts were presented in the Presidential Plenary Session on Tuesday Sept 25th. Out of the 5 presentations, two were presented by ATOMIC members (Stephen Liu, MD, on Impower 133 and Dr. Ross Camidge, MD, PhD, on ALTA-1L) each of which were supported with an associated synchronous New England of Journal of Medicine publication
Continue readingElena Shagisultanova, MD, PhD, Assistant Professor at the University of Colorado Denver Cancer Center and Lead Principal Investigator of the TULiP trial presented a trials-in-progress poster summarizing the study design for the ongoing trial in patients with hormone receptor positive and HER2-positive (HR+/HER2+) metastatic breast cancer.
Continue reading